SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis quarterly results beat expectations, with raised full-year guidance and a new 2027 outlook drawing bullish reactions. Traders remain divided over whether the strong report can sustain a rebound or whether the stock will repeat its pattern of fading after earnings.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPals quarterly results and raised full-year earnings outlook are driving attention: traders point to earnings and operating-income beats, while revenue and payment volume fell short of estimates. The stocks decline despite the guidance raise has left the community divided between optimism about the results and frustration over weak growth and the muted market reaction.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms $63 billion financing arrangement to supply AI chips and networking equipment to Anthropic is driving attention, with traders viewing it as a sign of future demand. Others question the financing and residual-value risks, and argue the news has not resolved the stocks relative weakness.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package and International Package. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is drawing attention after third-quarter results beat expectations and management raised its full-year outlook, though traders are debating the muted share-price reaction. Bulls point to a shift toward higher-margin shipments and network efficiencies, while skeptics question whether margins and peak-season execution can sustain the improvement as Amazon volume declines.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Cornings quarterly results modestly topped expectations, while its outlook pointed to continued growth, drawing attention ahead of the earnings reaction. Traders are split on whether the beat and guidance can overcome caution about the stocks history of post-earnings declines and whether strong results were already priced in.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas stronger-than-expected quarterly results and upbeat 2027 outlook, supported by demand for AI data-center infrastructure, drove the dominant discussion and a sharp post-report rebound after a steep selloff. Traders are divided on whether the growth outlook supports the valuation, citing concerns about margins, cash flow and customer concentration alongside optimism about sustained AI spending.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on the anticipated final analysis of SELLASs Phase 3 REGAL trial of GPS in AML, which is triggered at 80 events; traders are focused on when the milestone and topline results will be disclosed, with ASH as a possible venue for an update. Bulls interpret the prolonged wait as a sign patients may be living longer and speculate about a favorable readout or a buyout, while bears say the delay and company silence raise concerns about the trial and its results.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbeans Q3 earnings beat and higher full-year guidance drew attention, while a softer-than-expected Q4 outlook and expenses shifting into the next quarter prompted questions about the durability of the beat. Traders are weighing strong demand and bookings against near-term guidance concerns and debt risks.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention after a broad-market bounce, with traders linking the move to optimism around possible Iran de-escalation and strength in AI and semiconductor shares, while watching the Fed and major tech earnings. The reaction is divided: some expect the rally to continue, while others see a fragile, headline-driven bounce and anticipate a fade.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weaker-than-expected Q3 results and another cut to its 2026 outlook, now calling for an adjusted loss, are driving the discussion. Traders are largely concerned about continued declines, weak demand and debt, while some see the selloff as a potential bottom and hope managements conference-call comments offer reassurance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and -80.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging  C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Clene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Are Medical Stocks Lagging  BrightSpring Health Services, Inc. (BTSG) This Year?

Here is how BrightSpring Health Services, Inc. (BTSG) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’  

Equity

Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note. 

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of +38.00% and -62.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +15.39% and +0.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Clene (NASDAQ:CLNN) Major Shareholder Sells $34,827.95 in Stock

Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 5,795 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $6.01, for a total value of $34,827.95. Following the sale, the insider directly owned 271,774 shares in the...

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway.</li><li>Roth Capital analyst dismissed the chances of the drug getting approval on a surrogate endpoint.&nbsp;</li><li>The analyst, however, reiterated a ‘Buy’ rating on the stock and a $30 price target.</li></ul><p><br>Shares of Clene Inc. (CLNN) fell 3% after hours on Thursday after a Roth Capital analyst dismissed the chances of the U.S. Food and Drug Administration approving its application for the investigational therapy CNM-Au8 in the treatment of amyotrophic lateral sclerosis on an accelerated basis as a “long shot.”</p><p>Shares of the company rose 8% during regular trading hours but fell after hours following the analyst note.</p><h2 class="st-heading-2">Clene’s Plans For Its Investigational Therapy</h2><p>Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway. The FDA's Accelerated Approval pathway allows earlier approval of drugs treating serious or life-threatening conditions with unmet medical needs based on surrogate endpoints reasonably likely to predict clinical benefit, with mandatory confirmatory trials required post-approval to verify benefit.</p><p>The company’s submission will rely on data showing statistically significant reductions in neurofilament light chain — a key biomarker of neuronal damage — following a constructive meeting with the FDA in the first quarter. Regulators signaled that the NfL results, along with correlations to improved survival and clinical outcomes, may support accelerated approval for ALS, the company said.</p><p>“We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA,” said Clene CEO Rob Etherington. “People living with ALS continue to need additional treatment options, and we believe CNM-Au8 has the potential to restore and protect neuronal health and function, leading to improved survival.” The company also said on Thursday that it intends to launch a confirmatory late-stage trial in Q1 2027, with overall survival as the primary endpoint.</p><h2 class="st-heading-2">Analyst Weighs In On Plans</h2><p>Roth Capital analyst Jonathan Aschoff said that the FDA's agreement to receive Clene's accelerated approval NDA for CNM-Au8 in treating ALS is a positive development, but the firm does not believe that the magnitude of change in neurofilament light will drive approval.</p><p>The firm added that despite the dire ALS medical need, the much smaller NfL reduction with CNM-Au8 versus Biogen’s Qalsody stokes its pessimism. Qalsody is a prescription, FDA-approved medication specifically for adults with ALS, a progressive, fatal neurodegenerative disorder.</p><p>Roth, however, reiterated a ‘Buy’ rating on the stock and a $30 price target.</p><h2 class="st-heading-2">How Did CLNN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around CLNN stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.</p><p><a href="https://stocktwits.com/symbol/CLNN">CLNN stock</a> has gained over 165% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rgnx-stock-on-track-for-worst-day-ever-as-big-q1-loss-cash-concerns-eclipse-duchenne-trial-success/cZX1zjuReSX">RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

Global stock market chart and trading board - stock photo

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$3.84
Prev Close	$3.88
Open	$3.92
Dividend Yield	0.00%
50-Day Moving Average	$3.97
Beta	1.07
Avg. Volume	148,114.05
PE Ratio	-1.09

52-Week High	$13.50
52-Week Low	$3.02
Market Capitalization	$54.58M
EPS (Annual)	-$2.65
Price to Book	-1.98
Revenue Per Employee	$2,531.65

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLNN Fundamentals